U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H27NO4
Molecular Weight 357.4434
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Nispomeben

SMILES

C[C@H](O)COC[C@H](CC1=CC=C(O)C=C1)NC(=O)CCC2=CC=CC=C2

InChI

InChIKey=CDKPAWCGPQDCGU-LPHOPBHVSA-N
InChI=1S/C21H27NO4/c1-16(23)14-26-15-19(13-18-7-10-20(24)11-8-18)22-21(25)12-9-17-5-3-2-4-6-17/h2-8,10-11,16,19,23-24H,9,12-15H2,1H3,(H,22,25)/t16-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H27NO4
Molecular Weight 357.4434
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Wed Apr 02 07:15:32 GMT 2025
Edited
by admin
on Wed Apr 02 07:15:32 GMT 2025
Record UNII
470338M5XD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Nispomeben
INN  
Official Name English
nispomeben [INN]
Preferred Name English
N-{(2S)-1-(4-hydroxyphenyl)-3-[(2S)-2-hydroxypropoxy]propan-2-yl}-3-phenylpropanamide
Systematic Name English
Code System Code Type Description
FDA UNII
470338M5XD
Created by admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
PRIMARY
SMS_ID
300000052509
Created by admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
PRIMARY
NCI_THESAURUS
C211729
Created by admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
PRIMARY
INN
13124
Created by admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
PRIMARY
PUBCHEM
51033894
Created by admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
PRIMARY
CAS
1443133-41-2
Created by admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY
The exact mechanism of action of NRD135S.E1 is currently not elucidated. NRD135S.E1 does not appear to act directly through any of the mechanisms, receptors, enzymes, or channels known to be associated with pain, including opioid receptors. Studies using U87 glioblastoma cells indicated that NRD135S.E1 may function indirectly through modifying Lyn kinase signaling